Gyre Therapeutics 
Welcome,         Profile    Billing    Logout  
 4 Products   34 Diseases  4 Products   3 Trials   160 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ispronicline (AZD3480) / AstraZeneca
2006-004783-31: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine

Ongoing
2
50
Europe
AZD3480,
AstraZeneca AB
Schizophrenia
 
 
marzeptacog alfa (CB 813d) / GC Biopharma
2020-003371-18: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Factor VII deficiency, Glanzmann thrombasthenia, and Haemophilia A with inhibitors on prophylaxis Studio per valutare farmacocinetica, farmacodinamica, sicurezza ed efficacia di marzeptacog alfa (attivato) nel trattamento degli episodi emorragici in soggetti con il deficit di fattore VII, tromboastenia di Glanzmann o l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab.

Not yet recruiting
1/2
24
Europe
Marzeptacog alfa (activated), [MarzAA, CB813d, PF-05280602], Powder for solution for injection
Catalyst Biosciences, Inc., Catalyst Biosciences, Inc.
Factor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E) deficit di fattore VII, tromboastenia di Glanzmann (GT) e l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab (HAwI-E)., Inherited rare bleeding disorders in which blood cannot clot normally difetti ereditari della coagulazioni in cui il sangue non è in grado di coagulare normalmente, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
hydronidone (F351) / Gyre Therapeutics
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
10/24
10/24
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
06/28
10/28
ChiCTR-ONC-12002899: Phase I clinical study of hydronidone capsules in healthy Chinese subjects

Completed
1
90
 
oral administration of a single dose of 15 mg hydronidone ;oral administration of a single dose of 30 mg hydronidone ;oral administration of a single dose of 60 mg hydronidone ;oral administration of a single dose of 90 mg hydronidone ;oral administration of a single dose of 120 mg hydronidone ;oral administration of 90 mg hydronidone t.i.d for seven days ;oral administration of 120 mg hydronidone tid for seven days ;oral administration of 60 mg hydronidone tid for 28 days ;oral administration of a single dose of 30 mg hydronidone ;oral administration of a single dose of 60 mg hydronidone on day 1 and day 6，and oral administration of 60 mg hydronidone Q8h from day 3 to day 5 ;oral administration of a single dose of 120mg hydronidone
Wuhan Union Hospital; Level of the institution：, Shanghai Genomics
Tolerability and Pharmacokinetics
 
 
ChiCTR2200059683: Pharmacokinetic interaction between hydronidone capsule and Entecavir capsule in Healthy Chinese subjects

Not yet recruiting
1
12
 
Day 1 to 6: at about 07:30, 15:30, 23:30, take 60mg (2 tablets) of hydroxynitone capsule on an empty stomach with 200mL water; Day 7: Take 60mg (2 tablets) of hydroxynitone capsule orally on an empty stomach with 200mL water at around 07:30 Day 10 to 19: at about 07:30, entecavir capsu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Genomics Inc.
Not applicable
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ispronicline (AZD3480) / AstraZeneca
2006-004783-31: A Double-Blind, Randomised, Parallel-Group, Placebo-Controlled, MultiCentre, Phase IIa Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Ascending Multiple Oral Doses of AZD3480 in Schizophrenic Patients on Stable Antipsychotic Monotherapy with quetiapine, risperidone or olanzapine

Ongoing
2
50
Europe
AZD3480,
AstraZeneca AB
Schizophrenia
 
 
marzeptacog alfa (CB 813d) / GC Biopharma
2020-003371-18: Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Factor VII deficiency, Glanzmann thrombasthenia, and Haemophilia A with inhibitors on prophylaxis Studio per valutare farmacocinetica, farmacodinamica, sicurezza ed efficacia di marzeptacog alfa (attivato) nel trattamento degli episodi emorragici in soggetti con il deficit di fattore VII, tromboastenia di Glanzmann o l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab.

Not yet recruiting
1/2
24
Europe
Marzeptacog alfa (activated), [MarzAA, CB813d, PF-05280602], Powder for solution for injection
Catalyst Biosciences, Inc., Catalyst Biosciences, Inc.
Factor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E) deficit di fattore VII, tromboastenia di Glanzmann (GT) e l’emofilia A con inibitori attualmente in trattamento preventivo con una dose di emicizumab (HAwI-E)., Inherited rare bleeding disorders in which blood cannot clot normally difetti ereditari della coagulazioni in cui il sangue non è in grado di coagulare normalmente, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
hydronidone (F351) / Gyre Therapeutics
NCT05115942: Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.

Completed
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
10/24
10/24
NCT05905172: Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis

Recruiting
3
248
RoW
Hydronidone capsules, F351, The placebo capsules, N
Beijing Continent Pharmaceutical Co, Ltd.
Liver Fibrosis
06/28
10/28
ChiCTR-ONC-12002899: Phase I clinical study of hydronidone capsules in healthy Chinese subjects

Completed
1
90
 
oral administration of a single dose of 15 mg hydronidone ;oral administration of a single dose of 30 mg hydronidone ;oral administration of a single dose of 60 mg hydronidone ;oral administration of a single dose of 90 mg hydronidone ;oral administration of a single dose of 120 mg hydronidone ;oral administration of 90 mg hydronidone t.i.d for seven days ;oral administration of 120 mg hydronidone tid for seven days ;oral administration of 60 mg hydronidone tid for 28 days ;oral administration of a single dose of 30 mg hydronidone ;oral administration of a single dose of 60 mg hydronidone on day 1 and day 6，and oral administration of 60 mg hydronidone Q8h from day 3 to day 5 ;oral administration of a single dose of 120mg hydronidone
Wuhan Union Hospital; Level of the institution：, Shanghai Genomics
Tolerability and Pharmacokinetics
 
 
ChiCTR2200059683: Pharmacokinetic interaction between hydronidone capsule and Entecavir capsule in Healthy Chinese subjects

Not yet recruiting
1
12
 
Day 1 to 6: at about 07:30, 15:30, 23:30, take 60mg (2 tablets) of hydroxynitone capsule on an empty stomach with 200mL water; Day 7: Take 60mg (2 tablets) of hydroxynitone capsule orally on an empty stomach with 200mL water at around 07:30 Day 10 to 19: at about 07:30, entecavir capsu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Shanghai Genomics Inc.
Not applicable
 
 

Download Options